Epidermal growth factor receptor and radiotherapy;Receptor pro epidermální růstový faktor a jeho úloha v radioterapii

Klinicka Onkologie

Volumn 21, Issue 6, 2008, Pages 338-347

  Sirák, Igor ^a   Hatlova J ^a   Petera, J ^a   Vosmik M ^a   Ryska A ^a   Vosmikova H ^a  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

Author keywords

Epidermal growth factor receptor; Radiotherapy

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; MATUZUMAB;

ANGIOGENESIS; CANCER RADIOTHERAPY; CANCER RESISTANCE; CELL CYCLE REGULATION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; ENZYME INHIBITION; HUMAN; LUNG NON SMALL CELL CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; RADIATION DOSE; REVIEW;

ANIMALS; HUMANS; NEOPLASMS; RADIATION TOLERANCE; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 58149174388     PISSN: 0862495X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (147)

1. Kasid U, Pirollo K, Dritschilo A, et al. Oncogenic basis of radiation resistance. Adv Cancer Res 1993;61:195-233.
2. Haimovitz-Friedman A. Radiation-induced signal transduction and stress response. Radiat Res 1998;150:S102-S108.
3. Carpenter G. Receptors for epidermal growth factor and other polypeptide mitogens. Annu Rev Biochem 1987;56:881-914.
4. Yarden Y. The EGFR family and its ligands in human cancer: signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001;37(Suppl 4):S3-S8.
5. Watanabe T, Shintani A, Nakata M, et al. Recombinant human betacellulin. Molecular structure, biological activities, and receptor interaction. J Biol Chem 1994;269:9966-9973.
6. Chryssogelos SA, Dickson RB. EGF receptor expression, regulation, and function in breast cancer. Breast Cance Res Treat 1994;29:29-40.
7. Toyoda H, Komurasaki T, Uchida D, Morimoto S. Distribution of mRNA for human epiregulin, a differentially expressed member of the epidermal growth factor family. Biochem J 1997;326:69-75.
8. Wells A. EGF receptor. Int J Bioch Cell Biol 1999;31:637-643.
9. Schmidt-Ullrich RK, Dent P, Grant S, et al. Signal transduction and cellular radiation responses. Radiat Res 2000;153:245-257.
10. Schmidt-Ullrich RK, Contessa JN, Dent P, et al. Molecular mechanisms of radiation-induced accelerated repopulation. Radiat Oncol Investig 1999;7:321-330.
11. Ullrich A, Schlessinger J. Signal transduction by receptors with tyrosine kinase activity. Cell 1990;61:203-212.
12. Wiley HS. Trafficking of the ErbB receptors and its influence on signaling. Exp Cell Res 2003;284:78-88.
13. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004;59:21-26.
14. Lin SY, Makino K, Xia W, et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 2001;3:802-808.
15. Waugh MG, Hsuan JJ. EGF receptors as transcription factors: ridiculous or sublime?. Nat Cell Biol 2001;3:E209-E211.
16. Oksvold MP, Huitfeldt HS, Stang E, Madshus I. Localizing the EGF receptor. Nat Cell Biol 2002;4:22.
17. Verbeek BS, Andriaansen-Slot SS, Vroom TM, et al. Overexpression of EGFR and c-erbB2 causes enhanced cell migration in human breast cancer cells and NIH3T3 fibroblasts. FEBS Lett 1998;425:145-150.
18. Turner T, Chen P, Goodly LJ, Wells A. EGF receptor signaling enhances in vivo invasiveness of DU-145 human prostate carcinoma cells. Clin Exp Metastasis 1996;14:409-418.
19. Damstrup L, Rude Voldberg B, Spang-Thomsen M, et al. In vitro invasion of small-cell lung cancer cell lines correlates with expression of epidermal growth factor receptor. Br J Cancer 1998;78:631-640.
20. Xie H, Turner T, Wang MH, et al. In vitro invasiveness of DU-145 human prostate carcinoma cells is modulated by EGF receptor-mediated signals. Clin Exp Metastasis 1995;13:407-419.
21. Prakash I, Mathur RP, Kar P, et al. Comparative evaluation of cell proliferative indices and epidermal growth factor receptor expression in gastric carcinoma. Indian J Pathol Microbiol 1997;40:481-490.
22. Gibson S, Tu S, Oyer R, et al. Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation. J Biol Chem 1999;274:17612-17618.
23. Leu CM, Chang C, Hu C. Epidermal growth factor (EGF) suppresses staurosporine-induced apoptosis by inducing mcl-1 via the mitogen-activated protein kinase pathway. Oncogene 2000;19:1665-1675.
24. Payne SG, Brindley DN, Guilbert LJ. Epidermal growth factor inhibits ceramide-induced apoptosis and lowers ceramide levels in primary placental trophoblasts. J Cell Physiol 1999;180:263-270.
25. McClellan M, Kievit P, Auersperg N, et al. Regulation of proliferation and apoptosis by epidermal growth factor and protein kinase C in human ovarian surface epithelial cells. Exp Cell Res 1999;246:471-479.
26. Lan L, Wong NS. Phosphatidylinositol 3-kinase and protein kinase C are required for the inhibition of caspase activity by epidermal growth factor. FEBS Lett 1999;444:90-96.
27. Caraglia M, Abbruzzese A, Leardi A, et al. Interferon-alpha induces apoptosis in human KB cells through a stress-dependent mitogen activated protein kinase pathway that is antagonized by epidermal growth factor. Cell Death Differ 1999;6:773-780.
28. Di Marco M, Pierce JH, Fleming TP, et al. Autocrine interaction betveen TGF-alpha and the EGF receptor: Quantitative requirements for induction of the malignant phenotype. Oncogene 1992;4:831-838.
29. Morishige K, Kurachi H, Amemiya K. Evidence for the involvement of transforming growth factor alpha and epidermal growth factor receptor autocrine growth mechanism in primary human ovarian cancers in vitro. Cancer Res 1991;51:5322-5328.
30. Salomon DS, Brandt R, Ciardiello F, Normanno N. Epidermal growth factor-related peptides and their receptors in human malignances. Crit Rev Oncol Hematol 1995;19:183-232.
31. Hu G, Liu W, Mendelsohn J, et al. Expression of epidermal growth factor receptor and human papillomavirus E6/E7 proteins in cervical carcinoma cells. J Natl Cancer Inst 1997;89:1271-1276.
32. Walker RA, Dearing SJ. Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. Breast Cancer Res Treat 1999;53:167-176.
33. Ekstrand AJ, James CD, Cavanee WK, et al. Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. Cancer Res 1991;51:2164-2172.
34. Mendelsohn J, Baselga J. The EGF receptor family as targets for cancer therapy. Oncogene 2000;19:6550-6565.
35. Nicholson RI, Gee JM, Harper ME. EGFR and cancer prognosis. Eur J Cancer 2001;37 (Suppl 4):S9-S15.
36. Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002;94:1593-1611.
37. Arteaga CL. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 2002;29:3-9.
38. Grandis JR, Melhem MF, Barnes EL, et al. Quantitative immunohistochemical analysis of transformig growth factor-aplha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996;78:1284-1292.
39. Goldstein NS, Armin M. Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 2001;92:1331-1346.
40. Rusch V, Klimstra D, Venkatraman E, et al. Overexpression of me epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. Clin Cancer Res 1997;3:515-522.
41. Maurizi M, Almadori G, Ferrandina G, et al. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer 1996;74:1253-1257.
42. Wells A. Tumor invasion: role of growth factor-induced cell motility. Adv Cancer Res 2000;78:31-101.
43. Dickstein BM, Wosikowski K, Bates SE. Increased resistance to cytotoxic agents in ZR75B human breast cancer cells transfected with epidermal growth factor receptor. Mol Cell Endocrinol 1995;110:205-211.
44. Grandis JR, Melhem MF, Gooding WE, et al. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 1998;90:824-832.
45. Neskovic-Konstantinovic Z, Nikolic-Vukosavljevic D, Brankovic-Magic M, et al. Expression of epidermal growth factor receptor in breast cancer, from early stages to advanced disease. J Exp Clin Cancer Res 1999;18:347-355.
46. Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma.. Cancer Res 2002;62:7350-7356.
47. McKay JA, Murray LJ, Curran S, et al Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer 2002;38:2258-2264.
48. Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 2003;21:3798-3807.
49. Spano JP, Lagorce C, Atlan D, et al. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 2005;16:102-108.
50. Meert AP, Martin B, Delmotte P, et al. The role of EGF-R expression on patient survival in lung cancer: a systematic review with meta-analysis. Eur Respir J 2002;20:975-981.
51. Lee JC, Wang ST, Chow NH, et al. Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer 2002;38:1065-1071.
52. Leong JL, Loh KS, Putti TC, et al. Epidermal growth factor receptor in indifferentiated carcinoma of the nasopharyn Epidermal growth factor receptor in undifferentiated carcinoma of the nasopharynx. Laryngoscope 2004;114:153-157.
53. Leung TW, Cheung AN, Cheng DK, et al. Expressions of c-erbB-2, epidermal growth factor receptor and pan-ras proto-oncogenes in adenocarcinoma of the cervix: correlation with clinical prognosis. Oncol Rep 2001;8:1159-1164.
54. Giralt J, de las Heras M, Cerezo L, et .al. The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis. Radiother Oncol 2005;74:101-108.
55. Demiral AN, Sarioglu S, Birlik B, et al. Prognostic significance of EGF receptor expression in early glottic cancer. Auris Nasus Laryng 2004;31:417-424.
56. Eriksen JG, Steiniche T, Overgaard J. The influence of epidermal growth factor receptor and tumor differentiation on the response to accelerated radiotherapy of squamous cell carcinomas of the head and neck in the randomized DAHANCA 6 and 7 study. Radiother Oncol 2005;74:93-100.
57. Barker FG, Simmons ML, Chang SM, et al. EGFR overexpression and radiation response in glioblastoma multiforme. Int J Radiat Oncol Biol Phys 2001;51:410-418.
58. Giralt J, Eraso A, Armengol M, et al. Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy. Int J Radiat Oncol Biol Phys 2002;54:1460-1465.
59. Krause M, Joiner MC, Baumann M. Ultrafractionation in human malignant glioma xenografts. Int J Cancer 2003;107:333.
60. Toulany M, Dittmann K, Baumann M, Rodemann HP. Inhibition of AKT/protein kinase b but not mitogen activated protein kinase/ERK modulates radiation response by EGFR antagonist. Radiother Oncol 2003;67:S20.
61. Fisher-Colbrie J, Witt A, Heinzl H, et al. EGFR and steroid receptors in ovarian carcinoma: comparison with prognostic parameters and outcome of patients. Aticancer Res 1997;17:613-619.
62. Klijn JG, Look MP, Portengen H, et al. The prognostic value of epidermal growth factor receptor (EGF-R) in primary breast cancer: results of a 10 year follow-up study. Breast Cancer Res Treat 1994;29:73-83.
63. Selvaggi G, Novello S, Torri V, et al. Epidermal growth factor receptor overexpression correlates with a poor prognosis in completely resected non-small-cell lung cancer. Ann Oncol 2004;15:28-32.
64. Shinojima N, Tada K, Shiraishi S, et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 2003;63:6962-6970.
65. Zhu A, Shaeffer J, Kolm P, El-Mahdi AM. Epidermal growth factor receptor: an independent predictor of survival in astrocytic tumors given definitive irradiation. Int J Radiat Oncol Phys 1996;34:809-815.
66. Pillai MR, Jayaprakash PG, Nair MK. Tumour-proliferative fraction and growth factor expression as markers of tumour response to radiotherapy in cancer of the uterine cervix. J Cancer Res Clin Ocol 1998;124:456-461.
67. Chua DT, Nicholls JM, Sham JS, Au GK. Prognostic value of epidermal growth factor receptor expression in patients with advanced stage nasopharyngeal carcinoma treated with induction chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2004;59:11-20.
68. Eriksen JG, Steiniche T, Askaa J, et al. The prognostic value of epidermal growth factor receptor is related to tumor differentiation and the overall treatment time of radiotherapy in squamous cell carcinomas of the head and neck. Int J Radiat Oncol Biol Phys 2004;58:561-566.
69. Atasoy BM, Bentzen SM, Trott KR. The epidermal growth factor receptor is involved in accelerated repopulation in squamous cell carcinoma of the head and neck. Exp Strahlenther Klin Strahlenbiol 2004;13:39-41.
70. Liu TF, Tatter SB, Willingham MC, et al. Growth factor receptor expression varies among high-grade gliomas and normal brain: epidermal growth factor receptor has excellent properties for interstitial fusion protein therapy. Mol Cancer Ter 2003;2:783-787.
71. Bowers G, Reardon D, Hewitt T, et al. The relative role of ErbB1-4 receptor tyrosine kinases in radiation signal transduction responses of human carcinoma cells. Oncogene 2001;20:1388-1397.
72. Contessa JN, Reardon DB, Todd D, et al. The inducible expression of dominant-negative epidermal growth factor receptor-CD533 results in radiosensitization of human mammary carcinoma cells. Clin Cancer Res 1999;5:405-411.
73. Reardon DB, Contessa JN, Mikkelsen RB, et al. Dominant negative EGFR-CD533 and inhibition of MAPK modify JNK1 activation and enhance radiation toxicity of human mammary carcinoma cells. Oncogene 1999;18:4756-4766.
74. Lammering G, Lin PS, Contessa JN, et al. Adenovirus-mediated overexpression of dominant negative epidermal growth factor receptor-CD533 as a gene therapeutic approach radiosensitizes human carcinoma and malignant glioma cells. Int J Radiat Oncol Biol Phys 2001;51:775-784.
75. Berkovcová J, Hajdúch M, Dziechciarková M, et al. Predikce účinnosti tyrozinkinázových inhibitorů Egfr1 v léčbě nemalobuněč ných plicních karcinomů. Klinická Onkologie 2006;19:171-176.
76. Contessa JN, Hampton J, Lammering G, et al. Ionizing radiation activates Erb-B receptor dependent Akt and p70 S6 kinase signaling in carcinoma cells. Oncogene 2002;21:4032-4041.
77. Kavanagh BD, Lin PS, Chen P, Schmidt-Ullrich RK. Radiation-induced enhanced proliferation of human squamous cancer cells in vitro: a release from inhibition by epidermal growth factor. Clin Cancer Res 1995;1:1557-1562.
78. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor donogen repopulation during radiotherapy. Acta Oncol 1988;27:131-146.
79. Baumann M, Petersen C, Eicheler W, et al. Mechanisms of repopulation in experimental squamous cell carcinoma. In: Kogelnik HD, Lukas P, Sedlmayer F. Progress in radiation-oncology, vol. 7. Bologna, Monduzzi; 2002, p.417-422.
80. Begg AC. Prediction of repopulation rates and radiosensitivity in human tumours. Int J Radiat Biol 1994;65:103-108.
81. Fowler JF. Rapid repopulation in radiotherapy: a debate on mechanism. The phantom of tumor treatment-continually rapid proliferation unmasked. Radiother Oncol 1991;22:156-158.
82. Milas L, Akimoto T, Hunter NR, et al. Relationship between cyclin D1 expression and poor radioresponse of murine carcinomas. Int J Radiat Oncol Biol Phys 2002;52:514-521.
83. Milas L, Yamada S, Hunter N, et al. Changes in TCD50 as a measure of clonogen doubling time in irradiated and unirradiated tumors. Int J Radiat Oncol Biol Phys 1991;21:1195-1202.
84. Amorino GP, Hamilton VM, Valerie K, et al. Epidermal growth factor receptor dependence of radiation-induced transcription factor activation in human breast carcinoma cells. Mol Biol Cell 2002;13:2233-2244.
85. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000;6:2166-2174.
86. Viloria-Petit A, Rak J, Hung MC, et al. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 1997;151:1523-1530.
87. Perrotte P, Matsumoto T, Inoue K, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 1999;5:257-265.
88. Huang SM, Li J, Armstrong EA, Harari PM. Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 2002;62:4300-4306.
89. Zips D, Baumann M. Anti-VEGF strategies in combination with radiotherapy. In: Nieder C, Milas L, Ang K. Modification of radiation response, Berlin, Springer; 2003, p.179-188.
90. Petersen C, Eicheler W, Frommel A, et al. Proliferation and micromilieu during fractionated irradiation of human FaDu squamous cell carcinoma in nude mice. Int J Radiat Biol 2003;79:469-477.
91. Schreiber AB, Lax I, Yarden Y, et al. Monoclonal antibodies against receptor for epidermal growth factor induce early and delayed effects of epidermal growth factor. Proc Natl Acad Sci USA 1981;78:7535-7539.
92. Masui H, Kawamoto T, Sato JD, et al. Growth inhibition of human tumor cells in athymic mice by anti-epidermal growth factor receptor monoclonal antibodies. Cancer Res 1984;44:1002-1007.
93. Modjahedi H, Affleck K, Stubberfield C, Dean C. EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5. Int J Oncol 1998;13:335-342.
94. Saleh MN, Raisch KP, Stackhouse MA, et al. Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation. Cancer Biother Radiopharm 1999;14:451-463.
95. Huang SM, Harari PM. Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. Invest New Drugs 1999;17:259-269.
96. Bianco C, Torota G, Bianco R, et al. Enhancement of antitumor activity of ionizing radiation by combined treatment with selective epidermal growth factor receptor - tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 2002;8:3250-3258.
97. Baumann M, Krause M, Zips D, et al. Selective inhibition of the epidermal growth factor receptor tyrosine kinase by BIBX1382BS and the improvement of growth delay, but not local control, after fractionated irradiation in human FaDu squamous cell carcinoma in the nude mouse. Int J Radiat Biol 2003;79:547-559.
98. Shintani S, Li C, Mihara M, et al. Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer. Int J Cancer 2003;107:1030-1037.
99. Sirotnak FM, Zakowski MF, Miller VA, et al. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 2000;6:4885-4892.
100. Prewett M, Rothman M, Waksal H, et al. Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clin Cancer Res 1998;4:2957-2966.
101. Overholser JP, Prewett MC, Hooper AT, et al. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 2000;89:74-82.
102. Gutowski MC, Briggs SL, Johnson DA. Epidermal growth factor receptor-reactive monoclonal antibodies: xenograft antitumor activity alone and as drug immunoconjugates. Cancer Res 1991;51:5471-5475.
103. Aboud-Pirak E, Hurwitz E, Pirak ME, et al. Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice. J Nat Cancer Inst 1988;80:1605-1611.
104. Yang XD, Jia XC, Corvalan JR, et al. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 1999;59:1236-1243.
105. Thomas SM, Grandis JR. Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev 2004;30:255-268.
106. Mendelsohn J. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 1997;3:2703-2707.
107. Goldstein NI, Prewett M, Zuklys K, et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995;1:1311-1318.
108. Bos M, Mendelsohn J, Bowden C et al. Phase I studies of anti-epidermal growth factor receptor (EGFR) chimeric monoclonal antibody C225 in patients with EGFR overexpressing tumors. Proc Am Soc Clin Oncol 1996;15:443a.
109. Brade AM, Magalhaes J, Siu L, et al. A single agent, phase I pharmacodynamic study of nimotuzumab (TheraCIM-h-R3) in patients with advanced refractory solid tumors [abstrakt]. J Clin Oncol 2007;25: abstrakt 14030.
110. Crombet T, Osorio M, Cruz T, et al. Use of the humanized antiepidermal growth factor receptor monoclonal antibody h-R3 in combination with radiotherapy in the treatment of locally advanced head and neck cancer patients. J Clin Oncol 2004;22:1646-1654.
111. Fry DW, Kraker AJ, McMichael A, et al. A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994;265:1093-1095.
112. Cohen MH, Williams GA, Sridhara R, et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets. Clin Cancer Res 2004;10:1212-1218.
113. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999;82:241-250.
114. Kashles O, Yarden Y, Fischer R, et al. A dominant negative mutation suppresses the function of normal epidermal growth factor receptors by heterodimerization. Mol Cell Biol 1991;11:1454-1463.
115. Redemann N, Holzmann B, von Rüden T, et al. Anti-oncogenic activity of signalling-defective epidermal growth factor receptor mutants. Mol Cell Biol 1992;12:491-498.
116. Gonzales G, Crombet T, Torres T, et al. Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann Oncol 2003;14:461-466..
117. Garcia B, Neninger E, de la Torre A, et al. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res 2008;14:840-846.
118. Harari PM, Huang SM. Radiation response modification following molecular inhibition of epidermal growth factor receptor signaling. Semin Radiat Oncol 2001;11:281-289.
119. Lammering G. Molecular predictor and promising target: will EGFR become a star in radiotherapy? Radiother Oncol 2005;74:89-91.
120. Baumann M, Dubois W, Suit HD. Response of human squamous cell carcinoma xenografts of different sizes to irradiation: relationship of clonogenic cells, cellular radiation sensitivity in vivo, and tumor rescuing units. Radiat Res 1990;123:325-330.
121. Steel GG. Cell survival as a determinant of tumor resonse. In: Steel GG. Basic clinical radiobiology, 3rd ed. London, Arnold; 2002, p. 52-63.
122. Milas L, Mason K, Hunter N, et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000;6:701-708.
123. Baumann M, Krause M. Targeting the epidermal growth factor receptor in radiotherapy: radiobiological mechanisms, preclinical and clinical results. Radiother Oncol 2004;72:257-266.
124. Nasu S, Ang KK, Fan Z, et al. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys 2001;51:474-477.
125. Wrann MM, Fox CF. Identification of epidermal growth factor receptors in a hyperproducing human epidermoid carcinoma cell line. J Biol Chem 1979;254:8083-8086.
126. Balaban N, Moni J, Shannon M, et al. The effect of ionizing radiation on signal transduction: antibodies to EGF receptor sensitize A431 cells to radiation. Biochim Biophys Acta 1996;1314:147-156.
127. Buchsbaum DJ, Bonner JA, Grizzle WE, et al. Treatment of pancreatic cancer xenografts with Erbitux (IMC-C225) anti-EGFR antibody, gemcitabine, and radiation. Int J Radiat Oncol Biol Phys 2002;54:1180-1193.
128. Raben D, Buchsbaum DJ, Gillespie Y. Treatment of human intracranial gliomas with chimeric monoclonal antibody against the epidermal growth factor receptor increases survival of nude mice when treated concurrently with irradiation. Proc Am Assoc Cancer 1999;40:A1224.
129. Harari PM, Huang SM. Epidermal growth factor receptor modulation of radiation response: preclinical and clinical development. Semin Radiat Oncol 2002;12:21-26.
130. Bandyopadhyay D, Mandal M, Adam L, et al. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem 1998;273:1568-1573.
131. Raben D, Helfrich D, Chan D, et al. The effects of ZD1839 on cell signaling processes and its growth effects with radiation and chemotherapy in human non-small cell lung cancer cells in vitro. Clin Cancer Res 2001;7:3805s.
132. Rao GS, Murray S, Ethier SP. Radiosensitization of human breast cancer cells by a novel ErbB family receptor tyrosine kinase inhibitor. Int J Radiat Oncol Biol Phys 2000;48:1519-1528.
133. Williams KJ, Telfer BA, Stratford IJ, Wedge SR. ZD1839 ("Iressa"), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 2002;86:1157-1161.
134. She Y, Lee F, Chen J, et al. The epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 selectively potentiates radiation response of human tumors in nude mice, with a marked improvement in therapeutic index. Clin Cancer Res 2003;9:3773-3778.
135. Raben D, Bianco C, Milas L, Ang KK. Targeted therapies and radiation for the treatment of head and neck cancer: are we making progress? Semin Radiat Oncol 2004;14:139-152.
136. Stea B, Falsey RR, Carey SS, Martinez JD. Growth inhibition and radiosensitization of glioblastoma multiforme by the tyrosine kinase inhibitor ZD1839 (Iressa). Proc Am Assoc Cancer Res 2002;43:787.
137. Solomon B, Hagekyriakou J, Trivett M, et al. Potentiation of the antitumor effect of ionizing radiation by ZD1839 ("Iressa") in vitro and in vivo in A431 cells. Proc Am Assoc Cancer Res 2002;43:1002.
138. Williams KJ, Telfer BA, Stratford IJ, Wedge SR. ZD1839 ('Iressa'), a specific oral epidermal growth factor receptor-tyrosine kinase inhibitor, potentiates radiotherapy in a human colorectal cancer xenograft model. Br J Cancer 2002;86:1157-1161.
139. Solomon B, Hagekyriakou J, Trivett M, et al. EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor. Int J Radiat Oncol Biol Phys 2003;55:713-723.
140. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-1500.
141. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
142. Krause M, Baumann M, Thames HD. In regard to Solomon et al.: EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. IJROBP 2003;55:713-723. Int J Radiat Oncol Biol Phys 2003;57:300-301.
143. Kallman RF, editor. Rodent tumor models in experimental cancer therapy. New York, Pergamon; 1987, 310 pp.
144. Cohen RB, Falcey JW, Paulter VJ et al. Safety profile of the monoclonal antibody (MOAB) IMC-C225, an anti-epidermal growth factor receptor (EGFR) used in the treatment of EGFR-positive tumors. Proc Am Soc Clin Oncol 2000;19:A1862.
145. Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of antiepidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:3234-3243.
146. Vokes EE, Choy H. Targeted therapies for stage III non-small cell lung cancer: integration in the combined modality setting. Lung Cancer 2003;41:S115-S121.
147. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-578.